<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04492163</url>
  </required_header>
  <id_info>
    <org_study_id>EF-33</org_study_id>
    <nct_id>NCT04492163</nct_id>
  </id_info>
  <brief_title>Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM</brief_title>
  <official_title>EF-33: An Open-Label Pilot Study of OPTUNE® (TTFields, 200 Khz) With High Density Transducer Arrays for the Treatment of Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single arm, historical control pilot study aimed to test&#xD;
      the effectiveness and safety of TTFields delivered through high intensity arrays in recurrent&#xD;
      glioblastoma.&#xD;
&#xD;
      The Optune® System is an investigational , portable, battery operated medical device in this&#xD;
      study delivering 200 kHz TTFields to the brain using high intensity transducer arrays for the&#xD;
      treatment of patients at the age of 18 years or older with first or second recurrence of&#xD;
      Glioblastoma Multiforme (GBM)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optune® is a medical device that has been approved for the treatment of recurrent and newly&#xD;
      diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States.&#xD;
      Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.&#xD;
&#xD;
      TTFields intensity has been shown to be positively correlated with patient outcome. The new&#xD;
      transducer array design is expected to reduce skin heating and thus enable delivery of higher&#xD;
      TTFields intensities while keeping the safety profile of the treatment unchanged.&#xD;
&#xD;
      The purpose of the study is to test if delivering TTFields using high intensity transducer&#xD;
      arrays for recurrent GBM significantly improves the clinical outcome of patients, compared to&#xD;
      using the standard transducer arrays.&#xD;
&#xD;
      The study will enroll 25 patients.&#xD;
&#xD;
      All patients included in this clinical investigation are patients with histologically&#xD;
      confirmed diagnosis of GBM with first or second radiological disease progression per RANO&#xD;
      criteria.&#xD;
&#xD;
      In addition, all patients must meet all eligibility criteria.&#xD;
&#xD;
      Baseline assessments will be performed to confirm patient eligibility in the study.&#xD;
&#xD;
      Enrolled patients will be treated continuously with the device until disease progression per&#xD;
      RANO criteria or 18 months (the earlier of the two) unless any of the treatment&#xD;
      discontinuation conditions described under criteria for patient withdrawal or termination are&#xD;
      met.&#xD;
&#xD;
      Concurrent brain directed antitumor therapy or procedures beyond TTFields is prohibited.&#xD;
&#xD;
      TTFields treatment will start within 28 days following signing the informed consent.&#xD;
&#xD;
      After the initial visit, subjects will continue treatment at home, while pursuing normal&#xD;
      daily routines. Subjects are required to use the device for at least 18 hours a day. Short&#xD;
      breaks in treatment for personal hygiene and other personal needs is allowed. Total usage&#xD;
      time will be recorded and provided to the sponsor.&#xD;
&#xD;
      Subjects will be required to return to the clinic every 4 weeks and every 8 weeks after first&#xD;
      12 visits, until disease progression. At each study visit an examination by a physician and a&#xD;
      routine laboratory examination will be performed.&#xD;
&#xD;
      A contrast enhanced MRI of the head will be performed at baseline and every 4 weeks for the&#xD;
      first 24 weeks and then at least every 12 weeks, until disease progression.&#xD;
&#xD;
      A post-treatment termination visit will be performed approximately 30 days after&#xD;
      discontinuation of TTfields treatment or disease progression (the latter of the two).&#xD;
&#xD;
      Following disease progression, subjects will be contacted once per month by telephone to&#xD;
      answer basic questions about their health status.&#xD;
&#xD;
      Pathological analysis of GBM tumor samples, which may be obtained prior and during the study&#xD;
      period, will be performed based on subjects' consent to have an experimental pathological&#xD;
      examination of their tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>18 Months</time_frame>
    <description>PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>18 Months</time_frame>
    <description>Survival will be measured from date of enrollment until date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival at 6 months (PFS6)</measure>
    <time_frame>18 Months</time_frame>
    <description>The analysis will be estimated proportions of patients who are progression-free at 6 months based on the RANO criteria following the time of enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year and 2-year survival rates</measure>
    <time_frame>24 Months</time_frame>
    <description>The analyses will be performed based on estimated proportions of patients who are alive at one and two years following enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall radiological response</measure>
    <time_frame>18 Months</time_frame>
    <description>The percentage of patients who had either complete response or partial response per RANO criteria following enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and frequency of adverse events</measure>
    <time_frame>18 Months</time_frame>
    <description>The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological changes in resected GBM tumors following study treatment</measure>
    <time_frame>18 Months</time_frame>
    <description>Pathological changes in the tumors of patients who consented to have pathological analysis of their tumors and also underwent another surgical resection while on the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dependence of Progression Free Survival on TTFields dose delivered to the tumor bed</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dependence of Overall Survival on TTFields dose delivered to the tumor bed</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Experimental: TTFields</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TTFields</intervention_name>
    <description>TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.&#xD;
Other Names:&#xD;
• TTFields</description>
    <arm_group_label>Experimental: TTFields</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of GBM according to WHO classification criteria.&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Not a candidate for further radiotherapy or additional resection of residual tumor.&#xD;
&#xD;
          4. Patients with first or second radiological disease progression per RANO criteria&#xD;
             documented by MRI within 4 weeks prior to starting therapy with the following&#xD;
             restriction: disease progression must be either growth of the enhancing lesion or a&#xD;
             new lesion.&#xD;
&#xD;
          5. Karnofsky performance status ≥ 70&#xD;
&#xD;
          6. Life expectancy ≥ least 3 months&#xD;
&#xD;
          7. Participants of childbearing age must use highly effective contraception. An effective&#xD;
             method of birth control is defined as one that results in a failure rate of less than&#xD;
             1% per year when used consistently and correctly. The Investigator must approve the&#xD;
             selected method, and may consult with a gynecologist as needed.&#xD;
&#xD;
          8. All patients must understand and voluntarily sign an informed consent document prior&#xD;
             to any study related assessments/procedures being conducted.&#xD;
&#xD;
          9. Treatment start date at least 4 weeks out from brain surgery chemotherapy or&#xD;
             irradiation therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infratentorial or leptomeningeal disease&#xD;
&#xD;
          2. Treatment with Optune® (for newly diagnosed or recurrent disease) prior to enrollment.&#xD;
&#xD;
          3. Participation in another clinical treatment study during screening and treatment phase&#xD;
             of the study.&#xD;
&#xD;
          4. Pregnancy or breast-feeding.&#xD;
&#xD;
          5. Significant co-morbidities at baseline, as determined by the investigator:&#xD;
&#xD;
               1. Thrombocytopenia (platelet count &lt; 100 x 103/μL)&#xD;
&#xD;
               2. Neutropenia (absolute neutrophil count &lt; 1 x 103/μL)&#xD;
&#xD;
               3. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)&#xD;
&#xD;
               4. Significant liver function impairment - AST or ALT &gt; 3 times the upper limit of&#xD;
                  normal&#xD;
&#xD;
               5. Total bilirubin &gt; 1.5 x upper limit of normal&#xD;
&#xD;
               6. Significant renal impairment (serum creatinine &gt; 1.7 mg/dL, or &gt; 150 µmol/l)&#xD;
&#xD;
               7. History of any psychiatric condition that might impair patient's ability to&#xD;
                  understand or comply with the requirements of the study or to provide consent&#xD;
&#xD;
          6. Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic&#xD;
             devices in the brain, or documented clinically significant arrhythmias.&#xD;
&#xD;
          7. Evidence of increased intracranial pressure (midline shift &gt; 5mm, clinically&#xD;
             significant papilledema, vomiting and nausea or reduced level of consciousness)&#xD;
&#xD;
          8. Admitted to an institution by administrative or court order.&#xD;
&#xD;
          9. Known allergies to medical adhesives or hydrogel&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Vymazal, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice Na Homolce (Na Homolce Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonia Mahnig</last_name>
    <phone>+1 603 206 2337</phone>
    <email>clinicaltrials@novocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Vymazal, Prof. MD</last_name>
      <phone>+420 257 272 614</phone>
      <email>Josef.Vymazal@homolka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Aaron Rulseh, PhD</last_name>
      <email>aaron.rulseh@homolka.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Josef Vymazal, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.</citation>
    <PMID>20231676</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum In: JAMA. 2018 May 1;319(17):1824.</citation>
    <PMID>29260225</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.</citation>
    <PMID>26658786</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.</citation>
    <PMID>19387848</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <reference>
    <citation>Pless M, Weinberg U. Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs. 2011 Aug;20(8):1099-106. doi: 10.1517/13543784.2011.583236. Epub 2011 May 9.</citation>
    <PMID>21548832</PMID>
  </reference>
  <reference>
    <citation>Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1.</citation>
    <PMID>28765323</PMID>
  </reference>
  <reference>
    <citation>Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Haag P, Bomzon Z, Kirson ED, Weinberg U, Viktorsson K, Lewensohn R, Palti Y. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017 Dec 29;12(1):206. doi: 10.1186/s13014-017-0941-6.</citation>
    <PMID>29284495</PMID>
  </reference>
  <reference>
    <citation>Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.</citation>
    <PMID>29392280</PMID>
  </reference>
  <reference>
    <citation>Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1106-1113. doi: 10.1016/j.ijrobp.2019.04.008. Epub 2019 Apr 23.</citation>
    <PMID>31026557</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Recurrent Glioblastoma</keyword>
  <keyword>GBM</keyword>
  <keyword>Treatment</keyword>
  <keyword>Minimal Toxicity</keyword>
  <keyword>TTFields</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>NovoCure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04492163
org study id: EF-33
nct id: NCT04492163
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a prospective, open-label, single arm, historical control pilot study aimed to test
      the effectiveness and safety of TTFields delivered through high intensity arrays in recurrent
      glioblastoma.

      The Optune® System is an investigational , portable, battery operated medical device in this
      study delivering 200 kHz TTFields to the brain using high intensity transducer arrays for the
      treatment of patients at the age of 18 years or older with first or second recurrence of
      Glioblastoma Multiforme (GBM)
Optune® is a medical device that has been approved for the treatment of recurrent and newly
      diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States.
      Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.

      TTFields intensity has been shown to be positively correlated with patient outcome. The new
      transducer array design is expected to reduce skin heating and thus enable delivery of higher
      TTFields intensities while keeping the safety profile of the treatment unchanged.

      The purpose of the study is to test if delivering TTFields using high intensity transducer
      arrays for recurrent GBM significantly improves the clinical outcome of patients, compared to
      using the standard transducer arrays.

      The study will enroll 25 patients.

      All patients included in this clinical investigation are patients with histologically
      confirmed diagnosis of GBM with first or second radiological disease progression per RANO
      criteria.

      In addition, all patients must meet all eligibility criteria.

      Baseline assessments will be performed to confirm patient eligibility in the study.

      Enrolled patients will be treated continuously with the device until disease progression per
      RANO criteria or 18 months (the earlier of the two) unless any of the treatment
      discontinuation conditions described under criteria for patient withdrawal or termination are
      met.

      Concurrent brain directed antitumor therapy or procedures beyond TTFields is prohibited.

      TTFields treatment will start within 28 days following signing the informed consent.

      After the initial visit, subjects will continue treatment at home, while pursuing normal
      daily routines. Subjects are required to use the device for at least 18 hours a day. Short
      breaks in treatment for personal hygiene and other personal needs is allowed. Total usage
      time will be recorded and provided to the sponsor.

      Subjects will be required to return to the clinic every 4 weeks and every 8 weeks after first
      12 visits, until disease progression. At each study visit an examination by a physician and a
      routine laboratory examination will be performed.

      A contrast enhanced MRI of the head will be performed at baseline and every 4 weeks for the
      first 24 weeks and then at least every 12 weeks, until disease progression.

      A post-treatment termination visit will be performed approximately 30 days after
      discontinuation of TTfields treatment or disease progression (the latter of the two).

      Following disease progression, subjects will be contacted once per month by telephone to
      answer basic questions about their health status.

      Pathological analysis of GBM tumor samples, which may be obtained prior and during the study
      period, will be performed based on subjects' consent to have an experimental pathological
      examination of their tumors.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Single group assignment
primary purpose: Treatment
masking: None (Open Label)
masking description: Open label
measure: Progression free survival (PFS)
time frame: 18 Months
description: PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria.
measure: Overall Survival (OS)
time frame: 18 Months
description: Survival will be measured from date of enrollment until date of death.
measure: Progression Free Survival at 6 months (PFS6)
time frame: 18 Months
description: The analysis will be estimated proportions of patients who are progression-free at 6 months based on the RANO criteria following the time of enrollment.
measure: 1-year and 2-year survival rates
time frame: 24 Months
description: The analyses will be performed based on estimated proportions of patients who are alive at one and two years following enrollment.
measure: Overall radiological response
time frame: 18 Months
description: The percentage of patients who had either complete response or partial response per RANO criteria following enrollment
measure: Severity and frequency of adverse events
time frame: 18 Months
description: The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments
measure: Pathological changes in resected GBM tumors following study treatment
time frame: 18 Months
description: Pathological changes in the tumors of patients who consented to have pathological analysis of their tumors and also underwent another surgical resection while on the study
measure: Dependence of Progression Free Survival on TTFields dose delivered to the tumor bed
time frame: 18 months
measure: Dependence of Overall Survival on TTFields dose delivered to the tumor bed
time frame: 18 months
arm group label: Experimental: TTFields
arm group type: Experimental
description: Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.
intervention type: Device
intervention name: TTFields
description: TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
Other Names:
• TTFields
arm group label: Experimental: TTFields
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Josef Vymazal, MD, DSc
role: Principal Investigator
affiliation: Nemocnice Na Homolce (Na Homolce Hospital
last name: Antonia Mahnig
phone: +1 603 206 2337
email: clinicaltrials@novocure.com
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
country: Czechia
citation: Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
PMID: 20231676
citation: Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum In: JAMA. 2018 May 1;319(17):1824.
PMID: 29260225
citation: Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.
PMID: 26658786
citation: Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5.
PMID: 17551011
citation: Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.
PMID: 19387848
citation: Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083.
PMID: 15126372
citation: Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.
PMID: 22608262
citation: Pless M, Weinberg U. Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs. 2011 Aug;20(8):1099-106. doi: 10.1517/13543784.2011.583236. Epub 2011 May 9.
PMID: 21548832
citation: Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1.
PMID: 28765323
citation: Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Haag P, Bomzon Z, Kirson ED, Weinberg U, Viktorsson K, Lewensohn R, Palti Y. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017 Dec 29;12(1):206. doi: 10.1186/s13014-017-0941-6.
PMID: 29284495
citation: Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.
PMID: 29392280
citation: Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1106-1113. doi: 10.1016/j.ijrobp.2019.04.008. Epub 2019 Apr 23.
PMID: 31026557
responsible party type: Sponsor
mesh term: Glioblastoma